OncLive TV

Lyudmila A. Bazhenova, MD, discusses factors to consider when navigating the use of neoadjuvant vs adjuvant EGFR– and ALK-directed treatment strategies for patients with non–small cell lung cancer who express oncogenic drivers.

Benjamin Philip Levy, MD, discusses the evolution of antibody-drug conjugates in non-small cell lung cancer following updated data to be read out for this treatment population throughout 2023.

John N. Allan, MD, discusses the importance of understanding fixed-duration treatment approaches with BTK inhibitors and BCL2 inhibitors in patients with chronic lymphocytic leukemia, highlighting data within this treatment armamentarium.

Nicole Lamanna, MD, discusses how the use of novel agents could address resistance associated with current treatment options for patients with chronic lymphocytic leukemia.

Marina Kremyanskaya, MD, PhD, discusses disease and patient characteristics that influence the choice between hydroxyurea and interferon therapy for patients with polycythemia vera or essential thrombocythemia.

Joseph A. Sparano, MD, FACP, discusses developments in breast cancer diagnosis and treatment.

David R. Wise, MD, PhD, discusses the importance of germline and somatic testing in patients with metastatic castration-resistant prostate cancer, and the need for improved testing practices in clinical practice.

Michael Hurwitz, MD, PhD, discusses the ongoing investigation into the use of CAR T-cell therapies in patients with solid tumors, such as kidney cancers.

Adnan F. Danish, MD, discusses findings from a study evaluating the prevalence of patients with high-risk non-Hodgkin lymphoma who were eligible for bridging radiation therapy prior to receiving CAR T-cell therapy, as well as the outcomes of these patients following CAR T-cell therapy.

Marc J. Braunstein, MD, PhD, discusses the evolution of autologous stem cell transplantation and ongoing treatment needed to better determine when ASCT should be recommended for patients with multiple myeloma.

Paul D. Nathan, MBBS, PhD, FRCP, discusses the design of the phase 3 IMCgp100-202 trial of tebentafusp-tebn in patients with previously untreated, HLA-A*02:01–positive metastatic uveal melanoma, highlighting the key enrollment criteria of the randomized, open-label study.

Paul D. Nathan, MBBS, PhD, FRCP, discusses the rationale for launching the phase 3 IMCgp100-202 trial evaluating tebentafus in patients with previously untreated, HLA-A*02:01–positive metastatic uveal melanoma, as well as the mechanism of action of the agent.

Jason Porter, MD, discusses the potential role of the next-generation TKI taletrectinib in patients with ROS1-positive non–small cell lung cancer, according to data from the phase 2 TRUST-II trial.

Guru P. Sonpavde, MD, discusses the significance of data from the phase 3 CheckMate 901 trial of concurrent frontline nivolumab plus chemotherapy in metastatic or unresectable urothelial carcinoma.

Arpita Desai, MD, discusses the impact that the findings from the phase 3 CONTACT-03 trial had in patients with metastatic renal cell carcinoma.

Qian (Janie) Qin, MD, discusses upcoming areas of interest in the renal cell carcinoma armamentarium.

Melissa L. Johnson, MD, discusses the preliminary efficacy findings from the phase 1 RMC-6236-001 trial in patients with non–small cell lung cancer harboring KRAS mutations and details the significance of these findings for patients within the KRAS G12X-mutant NSCLC population.

Adrienne Phillips, MD, MPH, discusses the impact of CAR T-cell therapy on the treatment paradigm for patients with large B-cell lymphoma, highlighting key advancements in the decision-making process for CAR T-cell therapy selection.

Jeffrey S. Weber, MD, PhD, discusses the use of circulating-tumor DNA dynamics when guiding treatment decision-making in melanoma, according to data from the phase 2b mRNA-4157-P201/KEYNOTE-942 trial.

Manojkumar Bupathi, MD, MS, discusses treating patients with renal cell carcinoma in community vs academic settings.

Mylin A. Torres, MD, discusses using antibody-drug conjugates (ADCs) to treat patients with breast cancer.

Bernd Kasper, MD, PhD, discusses the significance of the FDA approval of nirogacestat for patients with desmoid tumors.

Cynthia Ma, MD, PhD, discusses the use of AKT inhibitors vs PI3K inhibitors in breast cancer.

Shridar Ganesan, MD, PhD, discusses the current limitations and advantages of leveraging circulating-tumor DNA to detect minimal residual disease in patients with cancer, as well as how ctDNA assays may address mechanisms of resistance in clinical practice.

M. Hamza Habib, MD, JD, MBA, FACP, FAAHPM, FRCPI, MRCP, discusses the development of novel technology-based strategies to improve palliative cancer for patients with cancer.

Pedro Barata, MD, MSc, discusses the biggest clinical trial updates to emerge for the treatment of patients with advanced renal cell carcinoma from the 2023 International Kidney Cancer Symposium.

Michael Hurwitz, MD, PhD, discusses the feasibility of utilizing CAR T-cell therapies in patients with solid tumors, such as kidney cancers.

Maurie Markman, MD, discusses the unique role of PARP inhibitors in the treatment of patients with ovarian cancer.

Omid Hamid, MD, director, Melanoma Program, The Angeles Clinic and Research Institute, Cedars-Sinai, discusses the rationale for a phase 1 trial of fianlimab plus cemiplimab in patients with advanced melanoma who have received prior adjuvant PD-1 inhibitors.

Lori A. Leslie, MD, discusses the benefits of implementing CAR T-cell therapy programs for patients with hematologic malignancies and highlights the successes with administering CAR T-cell therapy that JTCC has experienced.